What are the causes, diagnostic work‑up, and management options for low luteinising hormone (LH)?

Low Luteinising Hormone: Causes, Diagnosis, and Management

Low LH represents either secondary (hypogonadotropic) hypogonadism from hypothalamic-pituitary axis dysfunction or functional suppression from metabolic/systemic conditions, and management depends critically on whether fertility is desired—gonadotropin therapy for fertility preservation versus testosterone replacement when fertility is not a concern. 1

Classification and Causes

Low LH falls into three main categories that guide treatment decisions:

Secondary (Hypogonadotropic) Hypogonadism - Organic Causes

Congenital/Developmental:

• Idiopathic hypogonadotropic hypogonadism (IHH)
• Kallmann syndrome (with anosmia)
• Combined pituitary hormone deficiency
• Prader-Willi syndrome
• Isolated LH gene mutations 1

Acquired Structural:

• Pituitary adenomas (micro/macroadenomas)
• Hypothalamic tumors
• Traumatic brain injury
• Surgical hypophysectomy or cranial irradiation
• Inflammatory conditions (lymphocytic hypophysitis, sarcoidosis, granulomatous lesions)
• Langerhans histiocytosis 1

Drug-Induced (Critical to Identify):

• Oestrogens
• Testosterone or anabolic steroids (suppresses LH via negative feedback) 2
• Progestogens (including cyproterone acetate)
• Hyperprolactinaemia-inducing drugs
• Opiates
• GnRH agonists/antagonists
• Glucocorticoids 1

Functional Hypogonadism (Reversible)

This is diagnosed by excluding organic causes and should be addressed first before hormonal replacement:

• Obesity/metabolic syndrome/type 2 diabetes
• Chronic systemic diseases (HIV, chronic organ failure, chronic inflammatory arthritis)
• Cushing syndrome/glucocorticoid excess
• Eating disorders
• Endurance exercise
• Acute and critical illness
• Aging 1

Hyperprolactinaemia-Related

Elevated prolactin suppresses GnRH pulsatility, causing low LH—can result from pituitary masses or medications 1

Diagnostic Work-Up

Initial Assessment

Confirm the diagnosis with:

• Morning total testosterone levels (avoid testing during acute illness) 1
• Simultaneous LH and FSH measurement
• In males: Low testosterone + low/inappropriately normal LH confirms secondary hypogonadism 1
• In premenopausal females: Oligomenorrhea/amenorrhea + low estradiol + low LH/FSH 3
• In postmenopausal females: Absence of elevated FSH/LH is sufficient (if not on HRT) 3

Critical pitfall: GnRH stimulation testing offers no useful diagnostic information over baseline gonadotropin measurements with modern ultrasensitive assays 3

Identify Underlying Cause

Medication/substance review:

• Document all drugs affecting the HPG axis
• Assess for anabolic steroid use (22% of men on testosterone maintain suppressed LH throughout treatment) 2

Metabolic screening:

• BMI and waist circumference
• Screen for obesity, metabolic syndrome, type 2 diabetes
• Assess for Cushing's disease, acromegaly, insulin resistance 1

Pituitary evaluation:

• Prolactin level (exclude hyperprolactinaemia)
• Other pituitary hormones (TSH, free T4, cortisol, ACTH) to assess for combined deficiency 1, 3
• MRI of sella if structural lesion suspected 3

Fertility assessment:

• Semen analysis in males before starting testosterone (one study showed some men with acquired hypogonadotropic hypogonadism remained fertile after testosterone) 3
• Exclude pregnancy in amenorrheic women 3

Management Algorithm

Step 1: Address Reversible Causes First

For functional hypogonadism (obesity, metabolic disorders):

• Weight loss through low-calorie diets can reverse obesity-associated secondary hypogonadism
• Physical activity shows benefits correlating with exercise duration and weight loss
• Meta-analyses confirm normalization of gonadotropins with weight loss
• Caveat: Testosterone increases are modest (1-2 nmol/L), so combining lifestyle changes with testosterone therapy may yield better outcomes in symptomatic patients 1

Eliminate interfering medications when possible 1

Step 2: Hormonal Replacement Based on Fertility Goals

If Fertility is Desired (Males):

• Testosterone therapy is absolutely contraindicated 1
• Gonadotropin therapy is the standard treatment for secondary hypogonadism 1
• Recombinant hCG and FSH show comparable effects to urinary-derived preparations
• Combined hCG + FSH provides optimal outcomes 1
• In hypogonadotropic hypogonadism, hMG was clearly superior to purified FSH-only regimens 4

If Fertility is Desired (Females):

• Exogenous LH supplementation is beneficial in organic or functional hypogonadotropic hypogonadism 5
• Pulsatile GnRH (15 mcg/pulse subcutaneously every 90 minutes) achieved 93-100% cumulative pregnancy rates at 6 months in women with idiopathic hypogonadotropic hypogonadism, weight-related amenorrhea, and organic pituitary disease 6
• This approach is safer than exogenous gonadotropins with minimal monitoring needed, no hyperstimulation risk, and low multiple pregnancy rates 6

If Fertility is NOT a Concern (Males):

• Multiple testosterone formulations available
• Selection based on clinical characteristics, availability, patient preferences 1
• Important: 73% of men on testosterone therapy had at least one suppressed LH (<1 IU/ml) during treatment; intramuscular route increases suppression risk 2.44-fold 2

If Fertility is NOT a Concern (Postmenopausal Females):

• Standard hormone replacement therapy as clinically indicated 3

Step 3: Monitor and Adjust

Avoid common pitfalls:

• Never start testosterone in men desiring fertility—it will worsen hypogonadism via negative feedback
• Always exclude hyperprolactinaemia, thyroid disease, and hyperandrogenism in women with menstrual irregularities before diagnosing central hypogonadism 3
• In polycystic ovary syndrome with low LH, obesity, hyperandrogenism, and high baseline LH are adverse prognostic factors associated with high early pregnancy loss 6
• Assay variability exists for LH measurements—use the same assay for serial monitoring 3